Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Cost-effectiveness of a whole-area testing pilot of asymptomatic SARS-CoV-2 infections with lateral flow devices: A modelling and economic analysis study

View ORCID ProfileMark Drakesmith, Brendan Collins, Angela Jones, Kelechi Nnoaham, Daniel Thomas
doi: https://doi.org/10.1101/2021.05.10.21256816
Mark Drakesmith
1Communicable Disease Surveillance Centre, Public Health Wales, Cardiff, Wales, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Mark Drakesmith
  • For correspondence: mark.drakesmith@wales.nhs.uk
Brendan Collins
2Health and Social Services Group, Welsh Government, Cardiff, Wales, UK
3Department of Public Health, Policy and Systems, University of Liverpool, Liverpool, England, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Angela Jones
4Cwm Taf Morgannwg University Health Board, Abercynon, Rhondda Cynon Taf, Wales, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kelechi Nnoaham
4Cwm Taf Morgannwg University Health Board, Abercynon, Rhondda Cynon Taf, Wales, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Daniel Thomas
1Communicable Disease Surveillance Centre, Public Health Wales, Cardiff, Wales, UK
5School of Health Sciences, Cardiff Metropolitan University, Cardiff, Wales, UK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Background Mass community testing for SARS-CoV-2 by lateral flow devices (LFDs) aims to reduce prevalence in the community. However its effectiveness as a public heath intervention is disputed.

Method Data from a mass testing pilot in the Borough of Merthyr Tydfil in late 2020 was used to model cases, hospitalisations, ICU admissions and deaths prevented. Further economic analysis with a healthcare perspective assessed cost-effectiveness in terms of healthcare costs avoided and QALYs gained.

Results An initial conservative estimate of 360 (95% CI: 311-418) cases were prevented by the mass testing, representing a would-be reduction of 11% of all cases diagnosed in Merthyr Tydfil residents during the same period. Modelling healthcare burden estimates that 24 (16 - 36) hospitalizations, 5 (3-6) ICU admissions and 15 (11-20) deaths were prevented, representing 6.37%, 11.1% and 8.2%, respectively of the actual counts during the same period. A less conservative, best-case scenario predicts 2333 (1764-3115) cases prevented, representing 80% reduction in would-be cases. Cost effectiveness analysis indicates 108 (80-143) QALYs gained, an incremental cost ratio of £2,143 (£860-£4,175) per QALY gained and net monetary benefit of £6.2m (£4.5m-£8.4m). In the best-case scenario, this increases to £15.9m (£12.3m-£20.5m).

Conclusions A non-negligible number of cases, hospitalisations and deaths were prevented by the mass testing pilot. Considering QALYs gained and healthcare costs avoided, the pilot was cost-effective. These findings suggest mass testing with LFDs in areas of high prevalence (>2%) is likely to provide significant public health benefit. It is not yet clear whether similar benefits will be obtained in low prevalence settings or with vaccination rollout.

Competing Interest Statement

Dr Collins is seconded as Head of Health Economics in Welsh Government, this paper does not represent any views of Welsh Government.

Funding Statement

This study was performed as part of our ongoing epidemic response and no external sources of funding were used.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study was reviewed by the Public Health Wales Research and Development Office and determined to be usual practice in public health, and therefore did not require external NHS ethics committee approval. Investigation of communicable disease outbreaks and surveillance of notifiable disease is permitted under Public Health Wales Establishment Order. Data were held and processed under Public Health Wales information governance arrangements in compliance with the Data Protection Act, Caldicott Principles and Public Health Wales guidance on the release of small numbers. No data identifying protected characteristics of an individual were released outside Public Health Wales.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • Some restructuring and clarification to introduction and discussion. Cited some additional similar cost-effectiveness studies. Added supplementary analysis of cost-effectiveness thresholds.

Data Availability

Aggregated data on Covid-19 cases, hospitalizations and deaths is available on the Public Health Wales Rapid Covid-19 Surveillance Dashboard. Further anonymized data can be made available on reasonable request.

https://public.tableau.com/profile/public.health.wales.health.protection#!/vizhome/RapidCOVID-19virology-Public/Headlinesummary

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Back to top
PreviousNext
Posted March 08, 2022.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Cost-effectiveness of a whole-area testing pilot of asymptomatic SARS-CoV-2 infections with lateral flow devices: A modelling and economic analysis study
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Cost-effectiveness of a whole-area testing pilot of asymptomatic SARS-CoV-2 infections with lateral flow devices: A modelling and economic analysis study
Mark Drakesmith, Brendan Collins, Angela Jones, Kelechi Nnoaham, Daniel Thomas
medRxiv 2021.05.10.21256816; doi: https://doi.org/10.1101/2021.05.10.21256816
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Cost-effectiveness of a whole-area testing pilot of asymptomatic SARS-CoV-2 infections with lateral flow devices: A modelling and economic analysis study
Mark Drakesmith, Brendan Collins, Angela Jones, Kelechi Nnoaham, Daniel Thomas
medRxiv 2021.05.10.21256816; doi: https://doi.org/10.1101/2021.05.10.21256816

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Epidemiology
Subject Areas
All Articles
  • Addiction Medicine (230)
  • Allergy and Immunology (507)
  • Anesthesia (111)
  • Cardiovascular Medicine (1264)
  • Dentistry and Oral Medicine (207)
  • Dermatology (148)
  • Emergency Medicine (283)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (538)
  • Epidemiology (10056)
  • Forensic Medicine (5)
  • Gastroenterology (502)
  • Genetic and Genomic Medicine (2486)
  • Geriatric Medicine (240)
  • Health Economics (482)
  • Health Informatics (1653)
  • Health Policy (757)
  • Health Systems and Quality Improvement (638)
  • Hematology (250)
  • HIV/AIDS (538)
  • Infectious Diseases (except HIV/AIDS) (11896)
  • Intensive Care and Critical Care Medicine (627)
  • Medical Education (255)
  • Medical Ethics (75)
  • Nephrology (269)
  • Neurology (2304)
  • Nursing (140)
  • Nutrition (354)
  • Obstetrics and Gynecology (458)
  • Occupational and Environmental Health (537)
  • Oncology (1259)
  • Ophthalmology (377)
  • Orthopedics (134)
  • Otolaryngology (226)
  • Pain Medicine (158)
  • Palliative Medicine (50)
  • Pathology (326)
  • Pediatrics (737)
  • Pharmacology and Therapeutics (315)
  • Primary Care Research (282)
  • Psychiatry and Clinical Psychology (2295)
  • Public and Global Health (4850)
  • Radiology and Imaging (846)
  • Rehabilitation Medicine and Physical Therapy (493)
  • Respiratory Medicine (657)
  • Rheumatology (289)
  • Sexual and Reproductive Health (241)
  • Sports Medicine (228)
  • Surgery (273)
  • Toxicology (44)
  • Transplantation (131)
  • Urology (100)